These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 19476273)

  • 1. Emerging therapies for multiple myeloma.
    Dingli D; Rajkumar SV
    Oncology (Williston Park); 2009 Apr; 23(5):407-15. PubMed ID: 19476273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.
    Siegel DS; Vij R; Jakubowiak AJ
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):1-15. PubMed ID: 21928467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How best to use new therapies in multiple myeloma.
    Dingli D; Rajkumar SV
    Blood Rev; 2010 May; 24(3):91-100. PubMed ID: 20359801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Triplets therapy for the patients of multiple myeloma].
    Ishida T
    Nihon Rinsho; 2013 Sep; 71(9):1691-6. PubMed ID: 24205736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
    Richardson PG; Laubach J; Mitsiades C; Schlossman RL; Doss D; Colson K; McKenney ML; Noonan K; Warren DL; Ghobrial IM; Munshi NC; Anderson K
    Oncology (Williston Park); 2010 Mar; 24(3 Suppl 2):22-9. PubMed ID: 20518367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
    Moreau P
    Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
    Yaqub S; Ballester G; Ballester O
    Cancer Invest; 2013 Oct; 31(8):529-37. PubMed ID: 24083815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
    Lonial S; Cavenagh J
    Br J Haematol; 2009 Jun; 145(6):681-708. PubMed ID: 19344388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of bortezomib in the treatment of multiple myeloma].
    Gotoh A; Ohyashiki K
    Nihon Rinsho; 2007 Dec; 65(12):2309-14. PubMed ID: 18069278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role of novel combinations for induction therapy in multiple myeloma.
    Voorhees PM; Orlowski RZ
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):33-41. PubMed ID: 16879768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the management of multiple myeloma.
    Kumar L; Verma R; Radhakrishnan VR
    Natl Med J India; 2010; 23(4):210-8. PubMed ID: 21192514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversies in multiple myeloma: to transplant or not?
    Preeshagul IR; Van Besien K; Mark TM
    Curr Hematol Malig Rep; 2014 Dec; 9(4):360-7. PubMed ID: 25145553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.
    Jakubowiak A
    Semin Hematol; 2012 Jul; 49 Suppl 1():S16-32. PubMed ID: 22727389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
    van de Donk NW; Lokhorst HM
    Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
    van de Donk NW; Lokhorst HM; Dimopoulos M; Cavo M; Morgan G; Einsele H; Kropff M; Schey S; Avet-Loiseau H; Ludwig H; Goldschmidt H; Sonneveld P; Johnsen HE; Bladé J; San-Miguel JF; Palumbo A
    Cancer Treat Rev; 2011 Jun; 37(4):266-83. PubMed ID: 20863623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
    Greipp P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of relapsed/refractory multiple myeloma.
    Kastritis E; Palumbo A; Dimopoulos MA
    Semin Hematol; 2009 Apr; 46(2):143-57. PubMed ID: 19389498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.